Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EPS (Basic) (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of EPS (Basic) data on record, last reported at -$0.06 in Q4 2023.

  • For Q4 2023, EPS (Basic) rose 89.98% year-over-year to -$0.06; the TTM value through Dec 2023 reached -$3.21, down 436.04%, while the annual FY2024 figure was -$27.78, 765.42% down from the prior year.
  • EPS (Basic) reached -$0.06 in Q4 2023 per CGEM's latest filing, up from -$0.91 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.9 in Q2 2022 and bottomed at -$1.42 in Q1 2023.
  • Average EPS (Basic) over 4 years is -$0.3, with a median of -$0.47 recorded in 2020.
  • The widest YoY moves for EPS (Basic): up 1183.33% in 2022, down 898.72% in 2022.
  • A 4-year view of EPS (Basic) shows it stood at -$1.39 in 2020, then surged by 45.32% to -$0.76 in 2021, then increased by 21.21% to -$0.6 in 2022, then skyrocketed by 89.98% to -$0.06 in 2023.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.06 in Q4 2023, -$0.91 in Q3 2023, and -$0.82 in Q2 2023.